Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof

A hepatocyte growth factor and receptor inhibitor technology, which is applied to the pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and Bcl-2 inhibitor and its application field, which can solve the problem of high toxicity, patient intolerance, etc. question

Inactive Publication Date: 2015-03-25
BEIJING TIANHE RUITONG TECH DEV
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are many anti-tumor drugs on the market, such as alkylating agent drugs, antimetabolite drugs, anti-tumor antibiotics, immunomodulators, etc., but most of them are not tolerated by patients due to their high toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof
  • Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof
  • Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 The combination of different ratios of ABT-263 and PF-2341066 synergistically promotes the death of DLD1 cells, see Table 2.

[0062] Table 2

[0063]

[0064] In the experiment investigating the cell death of colon cancer cell line DLD1 caused by related compounds, it was found that when 0.75 μM ABT-263 or lower concentration was used alone, almost no cell death was found, even when 2.5 μM PF-2341066 was used alone, only about 15% of the cells were killed death; and when the two were combined at a lower concentration (0.5μM ABT-263+1.5μM PF-2341066), there was an obvious synergistic effect, resulting in the death of about 37% of cancer cells; when the two were combined with 0.75μM ABT- When the ratio of 263+2.5μM PF-2341066 is combined, a more significant synergistic effect is produced, resulting in the death of about 98% of cancer cells.

Embodiment 2

[0065] Example 2 The combination of different ratios of ABT-263 and EMD-1214063 synergistically promotes the death of DLD1 cells, see Table 3.

[0066] table 3

[0067]

[0068] In the experiment investigating the cell death of colon cancer cell line DLD1 caused by related compounds, it was found that when 0.75 μM ABT-263 or lower concentration was used alone, there was almost no cell death, even when 5.0 μM EMD-1214063 was used alone, only about 20% of the cells were killed death; and when the two were combined at a lower concentration (0.5μM ABT-263+4.0μM EMD-1214063), there was an obvious synergistic effect, resulting in the death of about 33% of cancer cells; when the two were combined with 0.75μM ABT- When the ratio of 263+5.0μM EMD-1214063 is combined, a more significant synergistic effect is produced, resulting in the death of 99% of cancer cells.

Embodiment 3

[0069] Example 3 The combination of different ratios of ABT-263 and PF-2341066 synergistically promotes the death of H-727 cells, see Table 4.

[0070] Table 4

[0071]

[0072]

[0073] In the experiment investigating the death of lung cancer cell line H-727 caused by related compounds, it was found that when 2.5 μM PF-2341066 or lower concentrations were used alone, less than 10% of the cells died, even when 1.0 μM ABT-263 was used alone About 20% of the cells died; and when the two were used together at a lower concentration (0.75μM ABT-263+1.5μM PF-2341066), there was an obvious synergistic effect, resulting in the death of about 29% of the cancer cells; when the two When the ratio of 1.0μM ABT-263+2.5μM PF-2341066 is combined, a more significant synergistic effect is produced, resulting in the death of about 92% of cancer cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composition containing a hepatic cell growth factor receptor (cMet) inhibitor and a Bcl-2 inhibitor and an application of the medicine composition in preparing medicine for treating colon cancers, liver cancers, lung cancers, kidney cancers, stomach cancers, brain tumors, sarcoma, glioma, pancreatic cancers, ovarian cancers, breast cancers or prostate cancers. The medicine composition containing the cMet inhibitor and the Bcl-2 inhibitor has a remarkable synergistic effect, and thereby the curative effect of medicine is improved, the medicine dosage is reduced and the side effect is reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition and its application in the preparation of medicines for treating cancer, in particular to a pharmaceutical composition containing hepatocyte growth factor receptor inhibitors and Bcl-2 inhibitors and its application in the preparation of medicines for treating colon cancer and liver cancer. , lung cancer, renal cancer, gastric cancer, brain tumor, sarcoma, glioma, pancreatic cancer, ovarian cancer, breast cancer or prostate cancer. Background technique [0002] The survey report of the World Health Organization shows that the global cancer situation is getting worse. In the next 20 years, the number of new patients will increase from the current 10 million to 15 million per year, and the number of deaths from cancer will also increase from 6 million to 10 million per year. Among them, lung cancer is one of the common malignant tumors. It originates from the bronchial epithelium at all levels and is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/5377A61K31/506A61K31/495A61P35/00A61K31/4545A61K31/47A61K31/475
Inventor 赵镭王利梅
Owner BEIJING TIANHE RUITONG TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com